02:21 AM EDT, 04/27/2026 (MT Newswires) -- AstraZeneca's (AZN.L, AZN.ST) Saphnelo received approval in the US for once-a-week subcutaneous self-administration through an autoinjector.

The US Food and Drug Administration approved the Saphnelo Pen for the treatment of adult patients with systemic lupus erythematosus in addition to standard therapy. The approval was based on results from the phase 3 Tulip-SC trial, according to a Monday filing from the healthcare company.